scholarly journals Chronic GVHD and Pretransplantation Abnormalities in Pulmonary Function Are the Main Determinants Predicting Worsening Pulmonary Function in Long-term Survivors after Stem Cell Transplantation

2006 ◽  
Vol 12 (12) ◽  
pp. 1261-1269 ◽  
Author(s):  
Bipin N. Savani ◽  
Aldemar Montero ◽  
Ramaprasad Srinivasan ◽  
Anurag Singh ◽  
Aarthi Shenoy ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Pulmonary Function ◽  
Cell Transplantation ◽  
Chronic Gvhd ◽  
Main Determinants ◽  
Long Term Survivors

Pulmonary function in very long-term survivors after allogeneic stem cell transplantation (aSCT)

2018 ◽  
Author(s):  
Ole Henrik Myrdal ◽  
Phoi Phoi Diep ◽  
Ellen Ruud ◽  
Johny Kongerud ◽  
Liv Ingunn Bjoner Sikkeland ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Pulmonary Function ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Long Term Survivors

Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD

Blood ◽  
2006 ◽  
Vol 108 (3) ◽  
pp. 1100-1105 ◽  
Author(s):  
Alicia Rovó ◽  
André Tichelli ◽  
Jakob R. Passweg ◽  
Dominik Heim ◽  
Sandrine Meyer-Monard ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Median Time ◽  
Chronic Gvhd ◽  
Time Interval ◽  
Hematopoietic Stem ◽  
Long Term Survivors

Abstract Factors associated with spermatogenesis after allogeneic hematopoietic stem cell transplantation (HSCT) were assessed in this prospective, single-center, cross-sectional study. All consecutive men aged 18 years or older and in complete remission 2 years or longer after HSCT were invited to participate. Seminal fluid analysis was performed on freshly collected samples according to World Health Organization guidelines. Between April 2003 and June 2004, 39 patients were included. The median age at semen analysis was 34 years (range, 20-59 years), and the median time interval between HSCT and sperm analysis 9 years (range, 2-20 years). Thirty-two patients (82%) underwent total body irradiation (TBI; ≥ 10 Gy) as part of their conditioning regimen. Eleven of 39 (28%) patients showed some spermatogenesis. Patients with detectable spermatozoa in the ejaculate were younger at HSCT (median age, 19 versus 28 years; P = .004), had a longer interval since HSCT (median time, 12 versus 7 years; P = .01), and were more often without chronic graft-versus-host disease (GvHD; 2 of 11 patients versus 16 of 28; P = .03). Nine of 16 patients (56%) undergoing transplantation when younger than age 25 years showed some degree of spermatogenesis. In conclusion, men who are long-term survivors, who were younger than 25 years at HSCT, and who apparently do not have chronic GvHD have a reasonable likelihood of spermatogenesis even when conditioned with standard-dose TBI.

scholarly journals What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?

2021 ◽  
Author(s):  
Steffen T. Simon ◽  
Anne Pralong ◽  
Michael Hallek ◽  
Christoph Scheid ◽  
Udo Holtick ◽  
...  
Keyword(s):  
Palliative Care ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Allogeneic Stem Cell Transplantation ◽  
Negative Impact ◽  
Chronic Gvhd ◽  
Care Needs ◽  
Post Transplantation

AbstractPatients undergoing allogeneic stem cell transplantation (allo-SCT) are given a real chance of cure, but at the same time are confronted with a considerable risk of mortality and of severe long-term impediments. This narrative, non-systematic literature review aims to describe the supportive and palliative care needs of allo-SCT recipients, including long-term survivors or those relapsing or dying after transplantation. It also evaluates the feasibility and effectivity of integrating palliative care early in transplant procedures. In this appraisal of available literature, the main findings relate to symptoms like fatigue and psychological distress, which appear to be very common in the whole allo-SCT trajectory and might even persist many years post-transplantation. Chronic GvHD has a major negative impact on quality of life. Overall, there is a paucity of research on further issues in the context of allo-SCT, like the distress related to the frequently unpredictable post-transplant trajectory and prognosis, as well as the end-of-life phase. First randomized controlled results support the effectiveness of early integration of specialized palliative care expertise into transplant algorithms. Barriers to this implementation are discussed.

scholarly journals Experience of severe fatigue in long-term survivors of stem cell transplantation

2007 ◽  
Vol 39 (10) ◽  
pp. 595-603 ◽  
Author(s):  
M F M Gielissen ◽  
A V M Schattenberg ◽  
C A H H V M Verhagen ◽  
M J Rinkes ◽  
M E J Bremmers ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Severe Fatigue ◽  
Long Term Survivors

scholarly journals Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation

Blood ◽  
2020 ◽  
Vol 135 (18) ◽  
pp. 1548-1559 ◽  
Author(s):  
Steffen Boettcher ◽  
C. Matthias Wilk ◽  
Jochen Singer ◽  
Fabian Beier ◽  
Elodie Burcklen ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Clonal Hematopoiesis ◽  
Increased Risk ◽  
Long Term Survivors

Abstract Clonal hematopoiesis (CH) is associated with age and an increased risk of myeloid malignancies, cardiovascular risk, and all-cause mortality. We tested for CH in a setting where hematopoietic stem cells (HSCs) of the same individual are exposed to different degrees of proliferative stress and environments, ie, in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their respective related donors (n = 42 donor-recipient pairs). With a median follow-up time since allo-HSCT of 16 years (range, 10-32 years), we found a total of 35 mutations in 23 out of 84 (27.4%) study participants. Ten out of 42 donors (23.8%) and 13 out of 42 recipients (31%) had CH. CH was associated with older donor and recipient age. We identified 5 cases of donor-engrafted CH, with 1 case progressing into myelodysplastic syndrome in both donor and recipient. Four out of 5 cases showed increased clone size in recipients compared with donors. We further characterized the hematopoietic system in individuals with CH as follows: (1) CH was consistently present in myeloid cells but varied in penetrance in B and T cells; (2) colony-forming units (CFUs) revealed clonal evolution or multiple independent clones in individuals with multiple CH mutations; and (3) telomere shortening determined in granulocytes suggested ∼20 years of added proliferative history of HSCs in recipients compared with their donors, with telomere length in CH vs non-CH CFUs showing varying patterns. This study provides insight into the long-term behavior of the same human HSCs and respective CH development under different proliferative conditions.

Sign in / Sign up

Export Citation Format

Share Document